OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases driven by biologically validated mutations. The company uses a structure-based drug design platform combining medicinal chemistry, x-ray crystallography, and computational chemistry to create small molecule therapies that target mutated proteins while sparing wild-type enzymes. Its lead product candidate is OKI-219, an oral selective inhibitor of PI3Kα H1047R being evaluated in Phase 1 clinical trials for advanced breast cancer and other solid tumors. OnKure also pursues discovery programs targeting other PI3Kα mutations and vascular malformations, designing its therapies for patients with genetically defined oncogenic alterations.

The company retains worldwide rights to all its development programs and conducts its clinical trials across international trial sites located in the United States, the European Union, and Asia. OnKure evaluates its therapies across global patient populations while planning future regulatory submissions and commercialization initiatives both domestically and internationally. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of OnKure Therapeutics's latest annual report, written by StockData.

“As of March 11, 2026, we had 45 employees, 34 of whom were engaged in research and development activities.”